Clinical Trials on Fatty Acid Levels in South Africa

Total 119 results

Medical University of South Carolina
Aker Biomarine Antarctic AS

Completed

Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's (RRIPP-3)

Fatty Acids, Omega-3 | Cognition | Nutrition | Resilience, Psychological | Psychology, Military

United States
Baxter Healthcare Corporation

Terminated

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Essential Fatty Acid Deficiency (EFAD)

United States
Cycle Pharmaceuticals Ltd.
Parexel

Completed

Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)

Hereditary Tyrosinemia, Type I

South Africa
Cycle Pharmaceuticals Ltd.
Parexel

Completed

Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)

Hereditary Tyrosinemia, Type I

South Africa
Cycle Pharmaceuticals Ltd.
Parexel

Completed

Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin

Hereditary Tyrosinemia, Type I

South Africa
Agricultural University of Athens
Laikο General Hospital, Athens

Recruiting

Effects of Time-restricted Hypocaloric Diet in Patients With NAFLD

Non-Alcoholic Fatty Liver Disease

Greece
Harokopio University
University of Novi Sad; National Research Council, Institute of Clinical Physiology...

Completed

Mastiha Treatment for Obese With NAFLD Diagnosis (MAST4HEALTH)

Non Alcoholic Fatty Liver Disease

Greece
Leiden University Medical Center
Maag Lever Darm Stichting

Not yet recruiting

The Clock Thickens: Morning or Evening Training for the Treatment of NAFLD? (TikTac)

Non-Alcoholic Fatty Liver Disease

Netherlands
Zimmer Biomet

Unknown

An MRI Investigation of Soft Tissues in Total Hip Arthroplasty (MoM_MRI)

Tissue Reaction | Elevated Blood Ion Levels

United States
Sangart

Completed

Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients

Shock, Hemorrhagic | Acidosis, Lactic | Shock, Traumatic

France, United Kingdom, South Africa, Germany
Inipharm Australia Pty Ltd

Recruiting

A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH

Non-alcoholic Steatohepatitis

Australia
Eccanga Pty Ltd
Syneos Health

Recruiting

FTIH Study of ECC0509 in Healthy Volunteers

Osteoarthritis | Nonalcoholic Steatohepatitis

Australia
Pronova BioPharma
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Completed

Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients

Non Alcoholic Fatty Liver

United States
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

Healthy | NASH - Nonalcoholic Steatohepatitis

Australia
Altimmune, Inc.

Completed

ALT-801 DDI Study in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

Australia
Blade Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

NASH - Nonalcoholic Steatohepatitis | Chronic Liver Disease

Australia
Pfizer

Completed

2-Week Study In People With Nonalcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

United States
Sheffield Teaching Hospitals NHS Foundation Trust
Bayer

Completed

Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS) (TEREPINS)

Hypogonadism | Nonalcoholic Steatohepatitis

United Kingdom
Poxel SA

Completed

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Nonalcoholic Fatty Liver

United States
Sagimet Biosciences Inc.

Completed

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Fatty Liver Disease

United States, Canada, Puerto Rico, Poland
Pfizer

Completed

6-week Safety and PD Study in Adults With NAFLD

Non-alcoholic Fatty Liver Disease

United States
Akero Therapeutics, Inc

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NASH/MASH | NAFLD/MASLD

United States, Canada, Puerto Rico, Australia, India
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Australia, Puerto Rico
Pfizer

Completed

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD)

United States
89bio, Inc.
ProSciento, Inc.

Completed

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NASH

United States, Puerto Rico
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

United States, Belgium, France, Puerto Rico, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Argentina, Australia, Canada, France, Israel, Italy, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine
Pfizer

Completed

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Israel, Taiwan, Canada, Australia, Poland
Novartis Pharmaceuticals

Terminated

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH) (NEXSCOT)

Non-alcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Germany, Argentina
Intercept Pharmaceuticals

Completed

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) (CONTROL)

Nonalcoholic Steatohepatitis

United States
GlaxoSmithKline

Recruiting

Phase 2b Study of GSK4532990 in Adults With NASH (HORIZON)

Nonalcoholic Fatty Liver Disease

United States, Australia, Italy, Japan, Spain, Belgium, Argentina, Canada, United Kingdom, Korea, Republic of, France, Greece, India, Mexico, Puerto Rico, Turkey, Panama
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Target PharmaSolutions, Inc.

Recruiting

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Steatohepatitis | Nonalcoholic Fatty Liver

United States, Germany, Spain
Madrigal Pharmaceuticals, Inc.

Unknown

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

United States
Akero Therapeutics, Inc

Active, not recruiting

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

NASH - Nonalcoholic Steatohepatitis

United States, Mexico, Puerto Rico
Poxel SA

Completed

Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
The George Institute

Not yet recruiting

Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis (BEST-DKA)

Diabetic Ketoacidosis

Australia
Immuron Ltd.

Completed

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis (NASH)

United States, Australia, Israel
ModernaTX, Inc.

Recruiting

A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

Methylmalonic Acidemia

United States, Spain, Canada, Netherlands, France, Australia, United Kingdom
Novo Nordisk A/S

Recruiting

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Non-alcoholic Steatohepatitis

United States, Korea, Republic of, Australia, Taiwan, Italy, Israel, Canada, Netherlands, Czechia, Malaysia, Spain, Denmark, China, United Kingdom, Singapore, Japan, Puerto Rico, Portugal, Switzerland, Ireland, Belgium, Romania, Ger... and more
Sangart

Completed

Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients

Shock, Hemorrhagic | Acidosis, Lactic | Shock, Traumatic

Norway, Singapore, Israel, France, United Kingdom, Germany, Switzerland, Australia, Brazil, South Africa, New Zealand, Colombia, Austria, Spain
Gilead Sciences
Novo Nordisk A/S

Active, not recruiting

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

Nonalcoholic Steatohepatitis

United States, Spain, Australia, France, Japan, Puerto Rico, Canada
Perspectum
King's College Hospital NHS Trust; University of Coimbra; Liverpool University... and other collaborators

Completed

Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan (RADIcAL1)

Metabolic Syndrome | NAFLD | NASH - Nonalcoholic Steatohepatitis

United Kingdom, Germany, Netherlands, Portugal
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Diabetes Mellitus, Type 2 | NAFLD | Hypertriglyceridemia | Fatty Liver, Nonalcoholic

United States, Canada
Novo Nordisk A/S

Completed

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

Non-alcoholic Steatohepatitis

United Kingdom, Spain, United States, France, Germany
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Non-alcoholic Steatohepatitis NASH

United Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
Novo Nordisk A/S

Active, not recruiting

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

Spain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...
Novartis Pharmaceuticals

Terminated

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. (ELIVATE)

Non Alcoholic Steatohepatitis (NASH)

United States, South Africa, Spain, Germany, Italy, Taiwan, Canada, Korea, Republic of, Singapore, Bulgaria, Estonia, Mexico, Japan, Denmark, United Kingdom, Colombia, Brazil, Belgium, Russian Federation, Puerto Rico, Chile, Argen... and more
Akero Therapeutics, Inc

Active, not recruiting

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (Harmony)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (ATLAS)

Nonalcoholic Steatohepatitis

Hong Kong, United States, Australia, Puerto Rico, New Zealand, Canada

Clinical Trials on Fatty Acid Levels in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations